AbbVie invests £120m in UK expansion
AbbVie has pledged another £120 million to the UK, reinforcing the country's recovery as a pharma industry investment hotspot.
Newsletters and Deep Dive digital magazine
AbbVie has pledged another £120 million to the UK, reinforcing the country's recovery as a pharma industry investment hotspot.
The BioInnovation Institute (BII) has expanded a European network to develop drugs for cardiometabolic diseases and launch new biotechs into Germany.
A gene therapy for alpha-1 antitrypsin deficiency developed by China's YolTech has successfully treated a patient with a severe form of the disease.
Merck KGaA has moved to streamline its focus with the sale of its contract development and manufacturing organisation (CDMO) business to Lonza.
Fresenius is already a player in the biosimilars market, and has ramped up its position via a deal with WuXi Bio that spans up to 37 candidates.
Editor's Picks
Newsletters and Deep Dive
digital magazine